1887

Chapter 45 : Antituberculosis Compounds Under Investigation

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Antituberculosis Compounds Under Investigation, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap45-1.gif /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap45-2.gif

Abstract:

New antituberculosis (anti-TB) drugs are needed due to the emerging and spreading resistance of to standard treatment such as isoniazid (INH), rifampin, pyrazinamide, ethambutol, or streptomycin. The AIDS pandemic stimulated research into and development of novel anti-TB agents; such agents have also been used to treat the opportunistic infections associated with AIDS such as complex (MAC) infections, pneumocystosis, toxoplasmosis, cryptosporidiosis, and fungal infections. Pyrazinamide is an important component of short-course chemotherapy against TB because of its activity against semidormant bacilli sequestered within macrophages. Some fluoroquinolones exhibit good activity against and are used in second-line therapy, because resistance mutations occur rapidly. Mycobacteria are relatively resistant to drying, alkali, and many chemical disinfectants, making it difficult to prevent the transmission of TB in institutions and in urban environments in general. The anatomical and the physiological structures of mycobacteria can be good targets for research of novel derivatives. N-Octanesulfonylacetamide (OSA) is an inhibitor of fatty acid and mycolic acid biosynthesis in mycobacteria. Ethambutol is an effective inhibitor of the arabinan component of arabinogalactan. Rhein is a dried root and is derived from the outer corky layer of .

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45

Key Concept Ranking

Type II Fatty Acid Synthase
0.405936
0.405936
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4
Figure 4

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 5
Figure 5

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 6
Figure 6

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 7
Figure 7

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 8
Figure 8

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 9
Figure 9

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 10
Figure 10

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 11
Figure 11

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 12
Figure 12

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 13
Figure 13

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 14
Figure 14

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 15
Figure 15

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 16
Figure 16

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 17
Figure 17

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 18
Figure 18

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 19
Figure 19

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 20
Figure 20

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 21
Figure 21

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 22
Figure 22

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 23
Figure 23

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 24
Figure 24

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 25
Figure 25

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 26
Figure 26

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 27
Figure 27

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 28
Figure 28

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 29
Figure 29

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 30
Figure 30

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 31
Figure 31

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 32
Figure 32

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 33
Figure 33

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 34
Figure 34

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 35
Figure 35

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 36
Figure 36

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 37
Figure 37

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 38
Figure 38

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 39
Figure 39

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815929.ch45
1. Andries K,, Verhasselt P,, Guillemont J,, Göhlmann HWH,, Neefs JM,, Winckler H,, Van Gestel J,, Timmerman P, et al, 2004, A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis, Sciences, online, 101126.
2. Anonymous, 2001, Tuberculosis drug screening program—search for new drugs for treatment of tuberculosis, Antimicrob Agents Chemother, 45, 19431946.
3. Ashtekar DR,, Costa-Perira R,, Nagrajan K,, Vishvanathan N,, Bhatt AD,, Rittel W, 1993, In vitro and in vivo activities of the nitro imidazole CGI 17341 against Mycobacterium tuberculosis, Antimicrob Agents Chemother, 37, 181186.
4. Bakkestuen PK,, Gundersen LL,, Langli G,, Liu F,, Nolsøe JMJ, 2000, 9-Benzyl purines with inhibitory activity against Mycobacterium tuberculosis, Bioorg Med Chem Lett, 10, 12071210.
5. Barry VC,, Belton JG,, Conalty ML,, Denneny JM,, Edward DW,, O’Sullivan JF,, Twomey D,, Winder F, 1957, A new series of phenazines (rimino-compounds) with high antituberculosis activity, Nature, 179, 10131015.
6. Berthelot P,, Debaert M,, Cremieux A,, Baghadi N, 1983, Analogues cycliques de l’éthambutol, activité anti-mycobactérie, Il Farmaco, 38, 7379.
7. Bettencourt MV,, Bosne-David S,, Amaral L, 2000, Comparative in vitro activity of phenothiazines against multi-drug resistant Mycobacterium tuberculosis, Intern J Antimicrob Agents, 16, 6971.
8. Biava M,, Fioravanti R,, Porretta GC,, Sleiter G,, Etterre A,, Deidda D,, Lampia G,, Pompei R, 1997, New toluidine derivatives with antimycobacterial and antifungal activities, Med Chem Res, 7, 228250.
9. Bosi S,, Da, Ros T,, Castellano S,, Banfi E,, Prato M, 2000, Antimycobacterial activity of ionic fullerene derivatives, Bioorg Med Chem Lett, 10, 10431045.
10. Bottari B,, Maccari R,, Montfort F,, Ottana R,, Rotondo E,, Vigorita MG, 2000, Isoniazid-related copper (II) and nickel (II) complexes with antimycobacterial in vitro activity, Part 9, Bioorg Med Chem Lett, 10, 657660.
11. Brennan PJ,, Nikaido H, 1995, The envelope of mycobacteria, Am Rev Biochem 64, 2963.
12. Brown FC, 1961, Chem Rev, 61, 463470.
13. Chakraborty A,, Gangdharam PR,, Damle P,, Pratt P,, Wright P,, Davidson PJ, 1981, Antituberculosis activity of 6-cyclooctylamino-5,8 quinolinoquinone, Tubercle, 62, 3741.
14. Charpentier P,, Guillot P,, Jacob R,, Gaudechon J,, Buisson P, 1952, Recherches sur les dimethylaminopropyl-N-phenothiazines, C R Acad Sci, 235, 5960.
15. Cocco MT,, Congiu C,, Onnis V,, Pusceddu MC,, Schivo ML,, De Logu A, 1999, Synthesis and antimycobacterial activity of some isonicotinoylhydrazones, Eur J Med Chem, 34, 10711076.
16. Cole ST, 2002, Comparative and functional genomics of M. tuberculosis complex, Microbiology, 148, 29192928.
17. Cox JS,, Chen B,, McNeil M,, Jacobs WR, 1999, Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice, Nature, 402, 7883.
18. Crowle AJ,, Douvas GS,, May MH, 1992, Chlorpromazine, a drug potentially useful for treating mycobacterial infections, Chemotherapy, 38, 410.
19. Cynamon M,, Lang M,, O’Railly T,, Chmielewski A,, Klemens S, 1997, In vitro and in vivo activities of new nitroimiazole derivatives against M. tuberculosis, 37th Intersci Conf Antimicrob Agents Chemother, abstract F-30, p 151.
20. Cynamon MH,, Alvarez-Freites Z,, Yeo A, et al, 2004, BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis, J Antimicrob Chemother, 53, 403405.
21. Cynamon MH,, Gimi R,, Guyenes T,, Sharp CA,, Bergmann KE,, Han HJ,, Grego LB,, Rapoma R,, Lucino G,, Welch JT, 1995, Pyrazinoic acid esters with broad-spectrum in vitro antimycobacterial activity, J Med Chem, 38, 39023907.
22. Cynamon MH,, Klemens SP,, Sharpe CA,, Chase S, 1999, Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model, Antimicrob Agents Chemother, 43, 11891191.
23. Deidda D,, Lampis G,, Fioravanti R,, Biava M,, Porretta GL,, Zanetti S,, Pompei S, 1998, Bactericidal activities of the pyrrole derivative BM 212 against multidrug-resistant and intra-macrophagic Mycobacterium tuberculosis strains, Antimicrob Agents Chemother, 42, 30353037.
24. De Logu A,, Onnis V,, Saddi B,, Congiu C,, Shiva ML,, Cocco M, 2002, Activity of a new class of isonicotinyl hydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis, J Antimicrob Chemother, 49, 275282.
25. Dong Y,, Xu C,, Zhao X,, Domagala J,, Drlica K, 1998, Fluoroquinolone action against mycobacteria: effect of C-8 substituents on growth, survival, and resistance, Antimicrob Agents Chemother, 42, 29782984.
26. Dong Y,, Xu C,, Zhao X,, Domagala J,, Drlica K, 1999, Effect of fluoroquinolone concentration on selection of mutants of Mycobacterium bovis BCG and Staphylococcus aureus, Antimicrob Agents Chemother, 43,17561758.
27. Escuyer VE,, White EL,, Ross J,, Cuningham AP,, Suling WJ, 2002, A putative folate pathway gene in the Mycobacterium tuberculosis genome codes for dihydroneopterin aldolase, a potential drug target, 32nd Intersci Conf Antimicrob Agents Chemother, abstract F-753.
28. Gadre DV,, Talwar V, 1999, In vitro susceptibility testing of Mycobacterium tuberculosis strains to trifluoperazine, J Chemother, 11, 203206.
29. Gezginci MH,, Martin AR,, Franzblau SG, 2001, Antimycobacterial activity of substituted isosteres of pyridine and pyrazine carboxylic acid, 2, J Med Chem, 44, 15601563.
30. Glickman MS,, Cox JS,, Jacobs WR, 2000, A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis, Mol Cell, 5, 717727.
31. Grandoni JA,, Marta PT,, Schloss JV, 1998, Inhibitors of branched-chain amino acid biosynthesis as potential antituberculosis agents, J Antimicrob Chemother, 42, 475482.
32. Guillemin I,, Sougaroff W,, Cambau E,, Revel-Viravau V,, Moreau N,, Jarlier V, 1999, Purification and inhibition by quinolones of DNA gyrases for Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv peregrinum, Microbiology, 154, 25272537.
33. Gundersen LL,, Nissen-Meyer J,, Spilberg B, 2002, Synthesis and antimycobacterial activities of 6-arylpurines, the requirements for the N-9 substituent in active antimycobacterial purines, J Med Chem, 45, 13831386.
34. Gürsoy A,, Karali N, 2000, 4-(3-Coumarinyl)-4-thiazolin-2-one benzylidenehydrazones with antituberculosis activity, Arzneim Forsch, 50, 167172.
35. Hartman GC, 2000, Molecular chaperonin inhibitors as novel anti-tuberculosis agents, 40th Intersci Conf Antimicrob Agents Chemother, abstract 2192, p 232.
36. Häusler H,, Kawakami RP,, Mlakor E,, Severn WB,, Stütz AE, 2001, Ethambutol analogue as potential antimycobacterial agent, Bioorg Med Chem Lett, 11, 161168.
37. Heifets L,, Lindhom-Levy P, 1992, Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations, Am Rev Resp Dis, 145, 12231225.
38. Igarashi M,, Nakagara N,, Hahori S,, Doi N,, Masuda T,, Yamazaki T,, Miyake T,, Ishizuka M,, Naganawa H,, Shomura T,, Omoto S,, Yano I,, Hamada M,, Takeuchi T, 2002, Caprazamycin A–F, novel anti-TB antibiotics from Streptomyces spp, 32nd Intersci Conf Antimicrob Agents Chemother, abstract F-2031.
39. Iguchi K,, Saitoh S,, Yamada Y, 1989, Novel 19-oxygenated sterols from the Okinawa soft coral Litophyton viridis, Chem Pharm Bull, 37, 25532554.
40. Jagannath C,, Reddy VM,, Kailasam S,, O’Sullivan JF,, Pattisapu R,, Gangadharam G, 1995, Chemotherapeutic activity of clofazimine and its analogs against Mycobacterium tuberculosis, in vitro, intracellular, and in vivo studies, Am J Resp Crit Care Med, 151, 10831086.
41. Karali N,, Kocabalkanli A,, Gürsoy A,, Ates Ö, 2002, Synthesis and antitubercular activity of 4-(3-coumarinyl)-3-cyclohexyl-4-thiazolin-2-one benzylidenehydrazones, Il Farmaco, 57, 589593.
42. Konig GM,, Wright AD,, Franzblau SC, 2000, Assessment of antimycobacterial activity of a series of mainly marine derived natural products, Planta Med, 66, 337342.
43. Kremer L,, Besra GS, 2002, Current status and future development of antitubercular chemotherapy, Expt Opin Invest Drugs, 11, 10331049.
44. Küçükgüzel SG,, Rollas S,, Küçükgüzel I,, Kiraz M, 1999, Synthesis and antimycobacterial activity of some coupling products from 4-aminobenzoic acid hydrazones, Eur J Med Chem, 34, 10931100.
45. Kushner S,, Dalalion H,, Sanjurjo JL,, Bach FL Jr,, Safir SR,, Smith VK Jr,, Williams JH, 1952, Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds, J Am Chem Soc, 74, 36173621.
46. Lin Y-M,, Flavin MT,, Cassidy CS,, Mar A,, Chen F-C, 2001, Biflavonoids as novel antituberculosis agents, Bioorg Med Chem Lett, 11, 21012104.
47. Maccari R,, Ottana R,, Monteforte F,, Vigorita MG, 2002, In vitro antimycobacterial activities of 2′-monosubstituted isonicotinohydrazides and their cyanoborane adducts, Antimicrob Agents Chemother, 46, 294299.
48. Matlola NM,, Steel HC,, Anderson R, 2001, Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine, J Antimicrob Chemother, 47, 199202.
49. McAdam RA,, Weisbrod TR,, Martin J,, Scuderi JD,, Brown AM,, Cirillo JD,, Bloom BR,, Jacobs WR, 1995, In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis, Infect Immun, 63, 10041012.
50. McKinney JD,, Honer zu, Bentrup K,, Munoz-Elias J, et al, 2000, Resistance of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase, Nature, 406, 735738.
51. McMillon FH,, Leonard F,, Meltzer RI,, King JA, 1952, Antitubercular substances. II. Substitution products of isonicotinic hydrazide, J Am Pharm Assoc, 42, 457464.
52. Morlock GP,, Crawford JT,, Butler RW,, Brim SE,, Sikes D,, Mazurek GH,, Woodley CL,, Cooksey RC, 2000, Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis, Antimicrob Agents Chemother, 44, 22912295.
53. Nasu SS,, Young BKS,, Hamann MT,, Scheuer PI,, Kelly-Borges M,, Goins KD, 1995, Puupehenone-related metabolite from Hawaiian sponges, Hyrtios spp, J Org Chem, 60, 72907292.
54. Nicolas P,, Tod M,, Padoin C,, Petitjean O, 1998, Clinical pharmacokinetics of diacerein, Clin Pharmacokinet, 35, 347359.
55. Oleksijew A,, Meulbroek J,, Ewing P,, Jarvis K,, Mitten M,, Paige L,, Tovcimak A,, Nukkula M,, Chu D,, Alder JD, 1998, In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains, Antimicrob Agents Chemother, 42, 26742677.
56. Onwuta US,, Kanyok TP,, Horgen FD, 1997, Extraction and antimycobacterial activity of an alkenyl resorcinol from Ardisia iwahigensis Elmer, 37th Intersci Conf Antimicrob Agents Chemother, abstract F-51, p 154.
57. Ottana R,, Maccari R,, Vigorita MG,, Rotondo E, 1998, Synthesis of mono and di-cyanoborane adducts from isoniconoylhydrazone and cyanoborohydre, J Chem Res, S, 550551.
58. Pagani G,, Pregnolato M,, Ubiali D,, Terreni M,, Piersimoni C,, Scaglione F,, Franschini F,, Rodriguez-Gascón A,, Pedraz Muñoz JL, 2000, Synthesis and in vitro antimycobacterium activity of N-alkyl-1,2-dihydro-2-thioxo-3-pyridine carbothioamides, preliminary toxicity and pharmacokinetic evaluation, J Med Chem, 43, 199204.
59. Parrish NM,, Houston T,, Jones PB,, Townsend G,, Dick JD, 2001, In vitro activity of a novel antimycobacterial compound, N-octanesulfonyl acetamide and its effects on lipid and mycolic acid synthesis, Antimicrob Agents Chemother, 45, 11431150.
60. Phetsuksiri B,, Baulard AA,, Cooper AM,, Minnikin DE,, Douglas JD,, Besra GS,, Brennan PJ, 1999, Antimycobacterial activity of isoxyl and new derivatives through the inhibition of mycolic acid synthesis, Antimicrob Agents Chemother, 43, 10421051.
61. Rastogi N,, Abaul J,, Goh KS,, Devallois A,, Philogene E,, Bourgeois P, 1998, Antimycobacterial activity of chemically defined natural substances from the Caribbean flora in Guadeloupe, FEMS Immunol Med Microbiol, 20, 267273.
62. Reddy PH,, Burra SS,, Murphy PS, 1992, Correlation between calmodulin-like protein, phospholipids and growth in glucose grown Mycobacterium phlei, Can J Microbiol, 38, 339342.
63. Reddy VM,, Nadadhur G,, Daneluzzi D,, O’Sullivan JF,, Gangadharam G, 1996, Antituberculosis activities of clofazimine and its new analogs B4154 and B4157, Antimicrob Agents Chemother, 40, 633636.
64. Reynolds RC,, White L,, Ross LM,, Seitz LE,, Moore G,, Leung A, 2000, Inhibitors of mycobacterial Ftsz polymerization, 40th Intersci Conf Antimicrob Agents Chemother, abstract 2030, p 226.
65. Rodriguez AD,, Ramirez C, 2001, Serrulatane diterpenes with antimycobacterial activity isolated from the West Indian sea whip Pseudopterogorgia elisabethae, J Nat Prod, 64, 100102.
66. Rodriguez AD,, Ramirez C,, Rodriguez GEM, 1999, Novel antimycobacterial benzoxazole alkaloid from the West Indian sea whip Pseudopterogorgia elisabethae, Org Lett, 1, 527531.
67. Rodriguez AD,, Ramirez C,, Rodriguez I,, Barnes CL, 2000, Novel terpenoids from the West Indian sea whip Pseudopterogorgia elisabethae (Bayer). Elisapterosins A and B—rearranged diterpenes possessing an unprecedented cagelike framework, J Org Chem, 65, 13901398.
68. Scorpio A,, Zhang Y, 1996, Mutations in pncA gene encoding pyrazinamidase/nicotaminidase cause resistance to the antituberculosis drug pyrazinamide in tubercule bacilli, Nat Med, 2, 662667.
69. Scozzafava A,, Mastobrenzo A,, Sapuran CT, 2001, Antimyco-bacterial activity of 9-sulfinylated/sulfonylated 6-mercaptopurine derivatives, Bioorg Med Chem Lett, 11, 16751678.
70. Sindelar G,, Zhao X,, Liew A,, Dong Y,, Lu T,, Zhou J,, Domagala J,, Drlica K, 2000, Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria, Antimicrob Agents Chemother, 44, 33373343.
71. Stover CK,, Warrener PG,, Sherman DR,, Van Devanter NH,, Langhome K,, Tanaka K,, Yan Y,, Barry CE,, Baker WR, 2000, A small molecule nitroimidazopyran drug candidate for the treatment of tuberculosis, Nature, 405, 962966.
72. Suling WJ,, Reynolds RC,, Barrow EW,, Wilson LN,, Piper JR,, Barrow WW, 1997, In vitro activity of lipophilic dihydrofolate reductase (DHFR) inhibitors against Mycobacterium tuberculosis and Mycobacterium avium complex, 37th Intersci Conf Antimicrob Agents Chemother, abstract F-42, p 153.
73. Suling WJ,, Reynolds RC,, Barrow EW,, Wilson LN,, Piper JR,, Barrow WW, 1998, Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase, Antimicrob Agents Chemother, 42, 811815.
74. Suling WJ,, Reynolds RC,, Piper JR,, Barrow EW,, Gundy LE,, Ginkel SZ,, Westbrook L,, Barrow WW, 1999, Vancomycin: structure activity studies of 2,4-diamino-5-deazapteridine derivatives as antimycobacterial agents and inhibitors of mycobacterial dihydrofo-late reductase (DHFR), 39th Intersci Conf Antimicrob Agents Chemother, abstract 1812, p 339.
75. Suling WJ,, Seitz LE,, Pathak V,, Westbrook L,, Barrow EW,, Zywno-Van-Ginkel S,, Reynolds RC,, Piper JR,, Barrow WW, 2000, Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase, Antimicrob Agents Chemother, 44, 27842793.
76. Takizawa Y,, Takashi M,, Takeda S,, Aburada M, 2003, Pharmacokinetics of rhein from onpi-to, an oriental herbal medicine, in rats, Biol Pharm Bull, 26, 613617.
77. Thangadurai D,, Viswanathan MB,, Ramesh N, 2002, Indigoferabietone, a novel abietane diterpenoid from Indigofera longeracemosa with potential antituberculous and antibacterial activity, Pharmazie, 57, 714715. (Retraction, 59:336, 2004.)
78. Torikata A,, Enokita R,, Okazaki T,, Nakajima M,, Iwado S,, Haneishi T,, Arai M, 1983, Mycoplanecins, novel anti-mycobacterial antibiotics from Actinoplanes awajinensis subsp mycoplanensis subsp nov—taxonomy of producing organism and fermentation, J Antibiotics, 36, 957960.
79. Ubiali D,, Pagani G,, Pregnolato M,, Piersimoni C,, Pedraz-Munoz JL,, Rodriguez-Gascon A,, Terreni M, 2002, New N-alkyl-1,2-dihydro-2-thioxo-3-pyridine carbothioamides as antituberculosis agents with improved pharmacokinetics, Bioorg Med Chem Lett, 12, 25412544.
80. Vanheusden V,, Meunier-Lehman H,, Pochet S,, Herdewij P,, Van Calenbergh S, 2002, Synthesis and evaluation of thymidine-5′-Omonophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase, Bioorg Med Chem Lett, 12, 26952698.
81. Van Rensburg CEJ,, Jonne GK,, Sirgel FA,, Matlola NM,, O’Sullivan JF, 2000, In vitro investigation of the antimicrobial activities of novel tetramethylpiperidine-substituted phenazines against Mycobacterium tuberculosis, Chemotherapy, 46, 4348.
82. Vigorita MG,, Basile M,, Zappala G,, Gabbrielli G,, Pizzimonti F, 1992, Halogenated isoniazid derivatives as possible antitubercular and anti-neoplasic agents, Il Farmaco, 47, 893906.
83. Vigorita MG,, Ottana R,, Zappala C,, Macacari R,, Pizzimonti FC,, Gabbrielli G, 1994, Halogenated isoniazid derivatives as posssible antimycobacterial and anti-HIV agents—III, Il Farmaco, 49, 775781.
84. Vittori N,, Collins M, 1996, Production of rhein and rhein derivatives, worldwide patents WO 96/ 30034.
85. Wächter GA,, Davis MC,, Martin AR,, Franzblau SG, 1998, Antimycobacterial activity of substituted isosteres of pyridine and pyrazine carboxylic acid 1, J Med Chem, 41, 24362438.
86. Wayne LG,, Sramek HA, 1994, Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis, Antimicrob Agents Chemother, 38, 20542058.
87. Welch J,, Chung WJ,, Kornilov A,, Brodsky B,, Higgins M,, Sanches T,, Spencer D,, Heifets L,, Cynamon MH, 2000, Novel aminomethylene analogs of pyrazinamide, PZA, possessing in vitro activity against M. tuberculosis in murine models of infection and intracellular activity against M. tuberculosis in infected human monocytes, 40th Intersci Conf Antimicrob Agents Chemother, abstract 2184, p 230.
88. White EL,, Suling WJ,, Ross LJ,, Seitz LE,, Reynold RC, 2002, 2-Alkoxy carbonyl amino pyridines, inhibitors of Mycobacterium tuberculosis FtsZ, J Antimicrob Chemother, 50, 111114.
89. Wilkinson RG,, Cantrall MB,, Sheperd RG, 1962, Antituberculous agents III, +,-2,2-(ethylenediamine,-di-1-butanol) and some analogs, J Med Pharm Chem, 5, 835845.
90. Xu C,, Kreiswirth BN,, Sreevatsan, S,, Musser JM,, Drlica K, 1996, Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multi-drug resistant Mycobacterium tuberculosis, J Infect Dis, 174, 11271130.
91. Youssef M,, el, Sayed K,, Roa KU, et al, 2002, Oxamanzamines: novel biocatalytic and natural products from manzamine producing Indo-Pacific sponges, Tetrahedron, 58, 73977402.
92. Zhao BY,, Pine R,, Domagala J,, Drlica K, 1999, Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis, effects of a C-8 methoxyl group on survival in liquid media and in human macrophages, Antimicrob Agents Chemother, 43, 661666.
93. Zurenko G,, Yagi BH,, Schaadt RD,, Al JW,, Kilburn JO,, Glickman SE,, Hutchins DK,, Barbachyn MR,, Brickner SJ, 1996, In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents, Antimicrob Agents Chemother, 40, 839845.

Tables

Generic image for table
Table 1

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 2

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 3

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 4

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 5

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 6

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 7

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 8

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 9

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 10

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 11

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 12

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 13

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 14

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 15

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 16

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45
Generic image for table
Table 17

Citation: Bryskier A. 2005. Antituberculosis Compounds Under Investigation, p 1146-1167. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch45

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error